



OP 16468

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David J. Grainger et al.

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

Docket No.: 295.022US1

Serial No.: 08/927,939

Filed: September 11, 1997

Due Date: July 7, 1999

Examiner: Prema Mertz

Group Art Unit: 1646

Assistant Commissioner for Patents

Washington, D.C. 20231

RECEIVED  
TECH CENTER 1500/2300

99 OCT 15 PM 1:46

We are transmitting herewith the following attached items (as indicated with an "X"):

- A return postcard.
- An Amendment and Response (12 Pages).
- Petition for Extension of Time (1 pg)
- A check in the amount of \$870.00 to cover the Extension of Time Fee.

**Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.**

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described above, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 7 day of October, 1999.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Janet E. Embretson  
Atty: Janet E. Embretson  
Reg. No. 39,665

**Customer Number 21186**

(GENERAL)

S/N 08/927,939

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David J. Grainger et al.

OCT 12 1999

Examiner: Prema Mertz

Serial No.: 08/927,939

Group Art Unit: 1646

Filed: September 11, 1997

Docket: 295.022US1

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN  
INFLAMMATORY RESPONSE

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Applicant has reviewed the Office Action mailed on April 7, 1999. Please amend the above-identified patent application as follows.

This response is accompanied by a Petition, as well as the requisite fee, to obtain a three-month extension of the period for responding to the Office Action, thereby moving the deadline for response from July 7, 1999 to October 7, 1999.

#12B  
Godium  
10  
19  
99

In the Claims

Please cancel claims 2, 5 and 12-41 without prejudice.

Please amend the claims as follows:

*B1*  
*B2*  
*B3*

(Amended) An isolated and purified peptide of a chemokine [Chemokine peptide 3], a variant, or a derivative thereof, comprising no more than 30 amino acid residues, wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, and wherein the peptide inhibits the activity of the corresponding native chemokine.

3. (Amended) The peptide of claim 1 which is not a peptide of [wherein the chemokine is not IL8] interleukin-8 (IL-8) or neutrophil activating protein-2 (NAP-2) [NAP-2].
4. (Amended) The peptide of claim 1 which is a variant of a peptide of [peptide 3 MCP-1] monocyte chemotactic protein-1 (MCP-1).
6. (Amended) The peptide of claim 1 [or 2] which is a peptide of a CC chemokine.
7. (Amended) The peptide of claim 6 wherein the CC chemokine is MCP-1, regulated on